Skip to main content
A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis. In a clinical study, the inhibition of a specific signaling pathway showed clear success in the treatment of granulomas in the skin. This opens up new therapeutic paths for sarcoidosis and similar inflammatory diseases. The results were recently published in the journal Lancet Rheumatology.
Join us this weekend! More than 25 sessions on topics ranging from spondyloarthritis, PsA, vasculitis and lupus to JAK i

Dr. John Cush RheumNow

2 years 8 months ago
Join us this weekend! More than 25 sessions on topics ranging from spondyloarthritis, PsA, vasculitis and lupus to JAK inhibitors, RA, artificial intelligence and myositis. CME and MOC offered. Learn more about our program and registration options today! https://t.co/Iac2T2Kohs https://t.co/zu1WJLOcmh
11-yr French study of #RA Pregnancies: more adverse Preg outcomes in RA, esp w/ active Dz. 11.8K RA vs 10.4 million no

Dr. John Cush RheumNow

2 years 8 months ago
11-yr French study of #RA Pregnancies: more adverse Preg outcomes in RA, esp w/ active Dz. 11.8K RA vs 10.4 million non-RA Pregs. 75% live births in RA. RA had more preterm(aOR 1.84), low birth wt (1.65), C-Sect (1.46), hospz (1.30), & prematurity (2.02)https://t.co/v9CmiPkIBG https://t.co/S0siiuG0oZ
Mexico survey of 250 RA pts -- 92% used complementary (CAM) therapies - mostly: herbals (65%), homeopathy (64%), cannabi

Dr. John Cush RheumNow

2 years 8 months ago
Mexico survey of 250 RA pts -- 92% used complementary (CAM) therapies - mostly: herbals (65%), homeopathy (64%), cannabis derivatives (51%). Poor DMARD adherence assoc w/ age (p=0.019), comorbidities (p=0.047), CAM use (p = 0.042) (OR 2.84) https://t.co/EGxyIVCMnk https://t.co/jjF5cH53we
FDA Safety Warning: denosumab now has a Boxed Warning for risk of severe hypocalcemia in CKD pts taking Prolia (usually

Dr. John Cush RheumNow

2 years 8 months ago
FDA Safety Warning: denosumab now has a Boxed Warning for risk of severe hypocalcemia in CKD pts taking Prolia (usually seen 2-10 wks post injx). Pts may or may not be symptomatic. CKD pts should have Ca and Creatinine monitored. https://t.co/tGiG35cOnv https://t.co/ITOZneGKtb
Rheumatologists and the Early Diagnosis of Spondyloarthritis

SPACE study of adults referred to rheumatology with less t

Dr. John Cush RheumNow

2 years 8 months ago
Rheumatologists and the Early Diagnosis of Spondyloarthritis SPACE study of adults referred to rheumatology with less than 2 years of chronic back pain (CBP), shows that only one-third can be reliably diagnosed with axial spondyloarthritis (axSpA). https://t.co/EwrrunyZs7. https://t.co/T0OqlsuU2P
Rheumatologists: What is your preferred MOA/Drug in treating Psoriatic Arthritis?

Dr. John Cush RheumNow

2 years 8 months ago
Rheumatologists: What is your preferred MOA/Drug in treating Psoriatic Arthritis?
The American College of Rheumatology (ACR), on behalf of over 9,100 rheumatologists and rheumatology professional team members, applauds the Centers for Medicare and Medicaid Services (CMS) for finalizing its Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations rule recently.  
Sodium Channels, Carbemazepine and Osteoarthritis Progression

A study published in Nature suggests that therapies affe

Dr. John Cush RheumNow

2 years 8 months ago
Sodium Channels, Carbemazepine and Osteoarthritis Progression A study published in Nature suggests that therapies affecting sodium channels could be employed to treat osteoarthritis. https://t.co/hmzKsgb3gA https://t.co/WVgk8nD4ne
You can still attend RheumNow Live!

Below is a preview of one of our "STEP" talks - by Mike Putman, MD, who brings his

Dr. John Cush RheumNow

2 years 8 months ago
You can still attend RheumNow Live! Below is a preview of one of our "STEP" talks - by Mike Putman, MD, who brings his vast knowledge to the forefront, shedding light on Myths & Mistakes on ANCA-Associated Vasculitis. https://t.co/LzcVytLDij Register: https://t.co/NWXKNhQzc5 https://t.co/ogAfTtH5Nk
On 1-19-2024, the Food and Drug Administration (FDA) issued a Drug Safety Communication about the risk of severe hypocalcemia in chronic kidney disease (CKD) patients taking denosumab for osteoporosis, with an accentuated risk in older women who are dialysis-dependent. This report is an update to their November 2022 investigation, the results of a related study being recently reported in JAMA.
×